Replimune Group, Inc. (REPL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.04-1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · REPL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete the commercial launch of TUDRIQEV (RP1) in the U.S. for advanced melanoma following FDA accelerated approval.
Stated as a priority in 2 recent disclosures including 2026-Q1 and August 2026 press releases. The FDA approved TUDRIQEV in August 2026 and the company began launch preparations with product expected in market within 60 days. Cash decreased from $268.9M at 2026-Q4 to $195.3M at 2026-Q1, partially offset by a $150M financing in August 2026 to support launch. The trajectory shows delivery on the commercial launch priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are completing the build out of our commercial infrastructure to enable a successful launch and bring TUDRIQEV to patients as quickly as possible.”
Resubmit the Biologics License Application for RP1 in combination with nivolumab and obtain FDA approval for advanced melanoma treatment.
Stated as a priority in 3 disclosures including 2026-Q1 and May 2026 press releases and August 2026 approval announcement. The FDA accepted the BLA resubmission with a goal date of August 2, 2026, and subsequently approved TUDRIQEV on August 6, 2026. This shows delivery on the regulatory approval priority.
“The FDA has accepted for review the resubmission of the BLA for RP1 with a goal date of August 2, 2026.”
Continue enrollment and progress in the IGNYTE-3 Phase 3 trial for RP1 and the REVEAL Phase 2/3 trial for RP2 in metastatic uveal melanoma.
Stated as a priority in 3 disclosures including 2026-Q1 press release and others. The IGNYTE-3 and REVEAL trials are actively enrolling with a Phase 2/3 transition for REVEAL expected in Q1 2027. This indicates ongoing progress consistent with management's stated clinical development priorities.
“The IGNYTE-3 Phase 3 trial is actively enrolling patients with advanced melanoma.”
“The REVEAL Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling.”
Control operating expenses and extend cash runway to support clinical development and commercialization plans.
Stated as a priority in 5 quarters from 2025-Q4 through 2026-Q4. Net losses have ranged from $86.7M in 2025-Q1 to $73.7M in 2026-Q4, showing a slight improvement. Cash reserves declined from $483.8M in 2025-Q4 to $268.9M in 2026-Q4, reflecting cash burn. The company expects cash to fund operations into early 2027, indicating limited progress but ongoing management focus on cash runway.
“Net loss was $73.7 million for the fiscal fourth quarter ended March 31, 2026.”
“Net loss was $70.9 million for the fiscal third quarter ended December 31, 2025.”
“Net loss was $83.1 million for the fiscal second quarter ended September 30, 2025.”
“Net loss was $86.7 million for the fiscal first quarter ended June 30, 2025.”
“The Company believes cash will fund operations into Q4 2026.”
Maintain collaborative communications with FDA to facilitate regulatory progress and product approval.
Stated as a priority in 2 disclosures including May 2026 and 2026-Q1 press releases. The company engaged in collaborative communications with FDA leading to BLA resubmission acceptance and a set goal date. This shows delivery on the strategic partnership priority.
“FDA accepted for review the resubmission of the RP1 BLA with a goal date of August 2, 2026.”
Over the trailing year it converted 0.96x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.